Alector Inc
ALEC
$5.09
Closing
▲0.39%
1D
▼-36.22%
YTD
Market cap
$487.36M
52 week high
$9.07
52 week low
$3.66
Volume
215,041
Check if the stock is halal
Unlock Industry-grade Shariah Compliance for global stocks. See results from 5 major Shariah standards: AAOIFI, S&P, DJIM, FTSE and MSCI.
We provide unparalleled value and service.
Screened by AAOIFI Certified Shariah Advisor & Auditor.
Get started from just $3.99/month
Market cap
$487.36M
Analysts' Rating
BUY
Price Target (Mean)
13.55556
Total Analysts
11
P/E
Operating Margin
-555.31%
Beta
0.82
Revenue Growth (Annual)
-35.48%
52 week high
$9.07
52 week low
$3.66
Div. Yield
%
EPS Annual Growth
-2749.60
Note on Purification and Zakat
- Purification and Zakat (for long-term investing) calculations are in USD per share and based on AAOIFI methodology. AAOIFI requires purification every financial period (e.g. quarterly).
- If you follow S&P Shariah’s Dividend-only purification, then remove the impure income % from the dividends you receive. No purification required for non-dividend paying stocks, according to S&P Shariah.
- For Zakat, if you did not invest in a company from a long term perspective, then consider the shares as trading goods and give 2.5% of the total value if a year has passed on them.
Company Profile
Alector, Inc. is a clinical-stage biopharmaceutical company. The Company is focused on immuno-neurology, a therapeutic approach for the treatment of neurodegenerative diseases. The Company is engaged in developing therapies designed to counteract these pathologies by restoring healthy immune function to the brain. Its research and drug discovery platform leverages human genetic datasets, advanced tools in bioinformatics and imaging, and insights in neurodegeneration and immunology to identify immune system. Its clinical programs include AL001 (latozinemab), AL101, and AL002. In addition, the Company also focuses on preclinical and research programs in its pipeline for indications, including Alzheimer’s disease, Parkinson’s disease, and oncology. Its first product candidate, latozinemab, is a humanized recombinant monoclonal antibody that increases the levels of progranulin (PGRN) in the brains of frontotemporal dementia carrying a progranulin (FTD-GRN) patients.
